Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04548999 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04548999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04548999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 3, 2020
Completion date
September 8, 2027
Enrollment
769 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis